The SURPASS clinical trial program, which evaluated tirzepatide for type 2 diabetes over periods extending to 52 weeks and beyond, demonstrated sustained glycemic improvements without evidence of significant tachyphylaxis (rapid tolerance development) for the primary glucose-lowering effects
Some users on weekly GLP-1 programs may be able to take a missed dose within 1-2 days of the scheduled time
It also promotes a better immune response and contributes to overall health and wellness
At Set Point Medical Weight Loss Clinic, we prioritize your safety and well-being
Accessed 01/08/2026 at Wharton, S., Freitas, P., Hjelmesth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., Garvey, W